(Q44695536)

5 December 2017

title

Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes (English)

1 reference

5 December 2017

1 reference

E Phielix

1

1 reference

5 December 2017

A Brehm

2

1 reference

5 December 2017

E Bernroider

3

1 reference

5 December 2017

M Krssak

4

1 reference

5 December 2017

C-H Anderwald

5

1 reference

5 December 2017

M Krebs

6

1 reference

5 December 2017

A I Schmid

7

1 reference

5 December 2017

P Nowotny

8

1 reference

5 December 2017

M Roden

9

1 reference

5 December 2017

publication date

1 May 2013

1 reference

Diabetes, Obesity and Metabolism

5 December 2017

published in

1 reference

5 December 2017

volume

15

1 reference

5 December 2017

issue

10

1 reference

5 December 2017

page(s)

915-922

1 reference

Getting the message across: mechanisms of physiological cross talk by adipose tissue

5 December 2017

cites work

1 reference

Direct stimulation of myocardial glucose transport and glucose transporter-1 (GLUT1) and GLUT4 protein expression by the sulfonylurea glimepiride

21 January 2018

1 reference

Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes

21 January 2018

1 reference

Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects

21 January 2018

1 reference

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

21 January 2018

1 reference

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes

21 January 2018

1 reference

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, cont

21 January 2018

1 reference

PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.

21 January 2018

1 reference

Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy.

21 January 2018

1 reference

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

Pioglitazone for diabetes prevention in impaired glucose tolerance.

21 January 2018

1 reference

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

Effects of pioglitazone in familial combined hyperlipidaemia

21 January 2018

1 reference

Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle

21 January 2018

1 reference

Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes

21 January 2018

1 reference

1H NMR relaxation times of skeletal muscle metabolites at 3 T.

21 January 2018

1 reference

Non-invasive studies of glycogen metabolism in human skeletal muscle using nuclear magnetic resonance spectroscopy

21 January 2018

1 reference

Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis

21 January 2018

1 reference

Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes

21 January 2018

1 reference

Splanchnic lipolysis in human obesity

21 January 2018

1 reference

Recent concepts in non-alcoholic fatty liver disease

21 January 2018

1 reference

Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes

21 January 2018

1 reference

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

21 January 2018

1 reference

21 January 2018

1 reference

Chronic peripheral hyperinsulinemia in type 1 diabetic patients after successful combined pancreas-kidney transplantation does not affect ectopic lipid accumulation in skeletal muscle and liver

21 January 2018

1 reference

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

21 January 2018

1 reference

Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes

21 January 2018

1 reference

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12112

1 reference

5 December 2017

1 reference